Rainbow Seed Fund News

— Early-stage venture fund key in bridging gap between UK research and commercialisation — Fund aims to turn UK scientific ‘world’s first’ ambitions into market-leading companies Rainbow Seed Fund, an early-stage venture capital fund focused on promising technologies developed at the UK’s largest publicly-funded research facilities and campuses, today announces that the fund have now […]

read more

CellCentric is developing first in class drug compounds against a key regulator of cancer. P300/CBP are twin (paralogue) histone acetyltransferase proteins, that act as transcriptional co-factors. When inhibited they cause the down regulation of the androgen receptor (AR) and its variants. It also decreases c-Myc, another key cancer driver. CellCentric has been focusing the use […]

read more

SynbiCITE and Rainbow Seed Fund today announce that Sir Richard Sykes, Chairman of the Royal Institution of Great Britain, Chairman of Imperial College Healthcare and Chancellor of Brunel University, will act as Chair of judges for theBio-start competition judging panel in 2017. Bio-start, a new annual competition founded by SynbiCITE and Rainbow Seed Fund, aims to incentivize innovative early-stage […]

read more

1 2 3 8